AmacaThera, a Toronto-based company commercializing hydrogel-based drug delivery platforms, has raised $3.25 million CAD in seed financing from Sprout BioVentures, Viva Biotech, and Grey Sky Venture Partners.  AmacaThera’s founding technology was discovered at the University of Toronto by Dr. Molly Shoichet, a leading expert on polymer design. AmacaThera envisions their proprietary technology to allow sustained and controllable release of diverse therapeutic agents from injectable, biocompatible hydrogels.  Their first product, AMT-143, targets superior post-operative pain control with the goal of eliminating opioid use following surgery.  The funding raised in this round will be used to advance AmacaThera’s drug delivery platform technology through a Phase I clinical trial.
UofT Engineering News

Chemical Engineering & Applied Chemistry, UofT

Comments are closed.